SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* BELANOFF JOSEPH K (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 275 MIDDLEFIELD ROAD (Street) MENLO PARK CA 94025 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/14/2004	3. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,404,345(1)	D
Common Stock	300,000	I	By Trust(2)
Common Stock	300,000	I	By Trust(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Subject to a right of repurchase by Corcept Therapeutics Incorporated

2. The reporting person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

	/s/ Fred Kurland, CFO of Corcept Therapeutics Incorporated attorney-in-fact	04/14/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY FOR SECTION 16 REPORTING
The undersigned hereby appoints Andrew Galligan, in his capacity as Chief
Financial Officer of Corcept Therapeutics Incorporated (the "Company"), or any
of his successors in any such office, as the attorney-in-fact of the undersigned to
execute and file with the Securities and Exchange Commission ("SEC") and any
other authority required by the rules and regulations of the SEC or any market or
exchange on which shares of the Company are traded and to submit to the
Company, in the place and stead of the undersigned, SEC Forms 3, 4 and 5 and
any successor reporting forms required by the SEC in connection with purchases
and sales of securities of the Company and any other transactions in securities of
the Company reportable on any such form.  This Power of Attorney shall be
effective until revoked by a written instrument executed by the undersigned and
delivered to the Company at its headquarters to the attention of the Chief Financial
Officer.
Dated:  February 5, 2002

/s/ Joseph K. Belanoff
Name:  Joseph K. Belanoff